Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageWe are a fully integrated, global, commercial-stage biotechnology company focused on the discovery, development, manufacturing and commercialization of genetic medicines to treat diseases with high unmet medical needs. Using our patented gene therapy technology platform that is based on engineered herpes simplex virus-1 (“HSV-1”), we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems.
In the company’s own words · 10-K filed Feb 17, 2026 · SEC EDGAR
Business segments
Q2 2026 · $119.2MThe company’s own SEC segment disclosure.
- United States$91.6M77%
- Europe$19.3M16%
- Japan$8.3M7%
Krystal Biotech, Inc. (KRYS) reported revenue of $119M in Q2 2026 (quarter ended Jun 30, 2026), up 24% from the same quarter a year earlier. That came with net income of $55M (46% of revenue). For the full year FY2025, revenue was $389M (+34% year on year) and net income $205M. Its largest region in Q2 2026 was United States at $92M, 77% of the disclosed total, well ahead of Europe at 16%.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.